抗肿瘤血管生成,肿瘤免疫治疗与肿瘤微环境的研究进展

被引：26

作者：

罗锋

王力

机构：

[1] 四川大学华西医院肺癌中心肿瘤中心生物治疗国家重点实验室

来源：

肿瘤预防与治疗 | 2016年 / 29卷 / 06期

关键词：

抗肿瘤血管生成; 肿瘤免疫治疗; 肿瘤微环境;

D O I：

暂无

中图分类号：

R730.5 [肿瘤治疗学];

学科分类号：

100214 [肿瘤学];

摘要：

抗肿瘤血管生成已是临床上肿瘤治疗的常用方法。但是,在此治疗过程中,肿瘤也会逐渐对抗血管生成药物产生耐药,这可能与肿瘤微环境的改变有关。怎样进一步改善抗肿瘤血管生成治疗疗效是目前的热点问题。最近有研究认为将其与肿瘤免疫治疗相联合可能是一种相互增益的治疗策略。本文就抗肿瘤血管生成治疗及其耐药、肿瘤微环境与肿瘤免疫治疗的关系,抗肿瘤血管治疗联合肿瘤免疫治疗的最新进展,进行综述。以期为今后探索肿瘤治疗新靶点、寻找肿瘤治疗新模式提供思路及参考依据,从而最终造福于广大癌症患者。

引用

页码：297 / 302+291 +291

页数：7

共 14 条

[1]

Versican silencing improves the antitumor efficacy of endostatin by alleviating. its induced inflammatory and immunosuppressive changes in the tumor microenvironment [J].

Wang, Zi ;

Li, Zhixi ;

Wang, Yuyi ;

Cao, Dan ;

Wang, Xia ;

Jiang, Ming ;

Li, Mei ;

Yan, Xi ;

Li, Yan ;

Liu, Yanyang ;

Luo, Feng .

ONCOLOGY REPORTS, 2015, 33 (06) :2981-2991

[2]

Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy.[J].N.A. Rizvi;S.J. Antonia;F.A. Shepherd;L.Q. Chow;J. Goldman;Y. Shen;A.C. Chen;S. Gettinger.International Journal of Radiation Oncology; Biology; Physics.2014, 5S

[3]

Enrichment and characterization of cancer stem-like cells from a cervical cancer cell line [J].

Wang, Li ;

Guo, Huijie ;

Lin, Caiyu ;

Yang, Liuqi ;

Wang, Xiujie .

MOLECULAR MEDICINE REPORTS, 2014, 9 (06) :2117-2123

[4]

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial [J].

Garon, Edward B. ;

Ciuleanu, Tudor-Eliade ;

Arrieta, Oscar ;

Prabhash, Kumar ;

Syrigos, Konstantinos N. ;

Goksel, Tuncay ;

Park, Keunchil ;

Gorbunova, Vera ;

Dario Kowalyszyn, Ruben ;

Pikiel, Joanna ;

Czyzewicz, Grzegorz ;

Orlov, Sergey V. ;

Lewanski, Conrad R. ;

Thomas, Michael ;

Bidoli, Paolo ;

Dakhil, Shaker ;

Gans, Steven ;

Kim, Joo-Hang ;

Grigorescu, Alexandru ;

Karaseva, Nina ;

Reck, Martin ;

Cappuzzo, Federico ;

Alexandris, Ekaterine ;

Sashegyi, Andreas ;

Yurasov, Sergey ;

Perol, Maurice .

LANCET, 2014, 384 (9944) :665-673

[5]

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial [J].

Reck, Martin ;

Kaiser, Rolf ;

Mellemgaard, Anders ;

Douillard, Jean-Yves ;

Orlov, Sergey ;

Krzakowski, Maciej ;

von Pawel, Joachim ;

Gottfried, Maya ;

Bondarenko, Igor ;

Liao, Meilin ;

Gann, Claudia-Nanette ;

Barrueco, Jose ;

Gaschler-Markefski, Birgit ;

Novello, Silvia .

LANCET ONCOLOGY, 2014, 15 (02) :143-155

[6]

Tanshinone IIA Inhibits Breast Cancer Stem Cells Growth In Vitro and In Vivo Through Attenuation of IL-6/STAT3/NF-kB Signaling Pathways [J].

Lin, Caiyu ;

Wang, Li ;

Wang, Hong ;

Yang, Liuqi ;

Guo, Huijie ;

Wang, Xiujie .

JOURNAL OF CELLULAR BIOCHEMISTRY, 2013, 114 (09) :2061-2070

[7]

Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor [J].

Henderson, Melissa A. ;

Yong, Carmen S. M. ;

Duong, Connie P. M. ;

Davenport, Alexander J. ;

John, Liza B. ;

Devaud, Christel ;

Neeson, Paul ;

Westwood, Jennifer A. ;

Darcy, Phillip K. ;

Kershaw, Michael H. .

IMMUNOTHERAPY, 2013, 5 (06) :577-590

[8]

Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma [J].

Lu-Emerson, Christine ;

Snuderl, Matija ;

Kirkpatrick, Nathaniel D. ;

Goveia, Jermaine ;

Davidson, Christian ;

Huang, Yuhui ;

Riedemann, Lars ;

Taylor, Jennie ;

Ivy, Percy ;

Duda, Dan G. ;

Ancukiewicz, Marek ;

Plotkin, Scott R. ;

Chi, Andrew S. ;

Gerstner, Elizabeth R. ;

Eichler, April F. ;

Dietrich, Jorg ;

Stemmer-Rachamimov, Anat O. ;

Batchelor, Tracy T. ;

Jain, Rakesh K. .

NEURO-ONCOLOGY, 2013, 15 (08) :1079-1087

[9]

Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo [J].

Yasuda, S. ;

Sho, M. ;

Yamato, I. ;

Yoshiji, H. ;

Wakatsuki, K. ;

Nishiwada, S. ;

Yagita, H. ;

Nakajima, Y. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2013, 172 (03) :500-506

[10]

TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice [J].

Welford, Abigail F. ;

Biziato, Daniela ;

Coffelt, Seth B. ;

Nucera, Silvia ;

Fisher, Matthew ;

Pucci, Ferdinando ;

Di Serio, Clelia ;

Naldini, Luigi ;

De Palma, Michele ;

Tozer, Gillian M. ;

Lewis, Claire E. .

JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (05) :1969-1973

← 1 2 →